This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (13)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Macular Degeneration  • Alert me on articles by topic  Social Bookmarking   What's this?

Andreas Kruger, MD; Bettina Matulla, MD; Michael Wolzt, MD; Stephan Pieh, MD; Karin Strenn, MD; Oliver Findl, MD; Hans-Georg Eichler, MD; Leopold Schmetterer, PhD

Arch Ophthalmol. 1998;116:27-30.

Objective  To study the ocular hemodynamic effects of a 3-month oral treatment with pentoxifylline in patients with nonexudative age-related macular degeneration.

Design  Double-blind, placebo-controlled, randomized, parallel group study.

Setting  Outpatient clinic of the Department of Ophthalmology, Vienna University, Vienna, Austria, that specializes in age-related macular degeneration.

Methods  Forty patients with age-related macular degeneration received pentoxifylline (400 mg 3 times a day orally, n=20) or placebo (n=20) for 3 months. Retinal blood flow was assessed by scanning laser Doppler flowmetry and pulsatile choroidal blood flow was assessed by laser interferometric measurement of fundus pulsation amplitude.

Main Outcome Measures  Changes in retinal blood flow and fundus pulsation amplitude.

Results  Four patients receiving pentoxifylline and 3 patients receiving placebo discontinued medication because of nausea. In the remaining subjects, the use of pentoxifylline increased ocular fundus pulsation amplitude (P<.001 vs placebo and baseline). The maximum increase was 28% after 3 months. In contrast, retinal blood flow was not changed by the use of pentoxifylline.

Conclusions  A 3-month course of oral pentoxifylline treatment increases choroidal but not retinal blood flow in patients with age-related macular degeneration. These data strongly support the concept that pentoxifylline might be useful in the treatment of age-related macular degeneration. Long-term clinical outcome trials are now warranted to test this hypothesis.

From the Departments of Clinical Pharmacology (Drs Kruger, Matulla, Wolzt, Eichler, and Schmetterer) and Ophthalmology (Drs Kruger, Pieh, Strenn, and Findl), and the Institute of Medical Physics (Dr Schmetterer), Vienna University, Vienna, Austria.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Effects of Pentoxifylline and Alprostadil on Ocular Hemodynamics in Healthy Humans
Dorner et al.
IOVS 2007;48:815-819.
ABSTRACT | FULL TEXT  

Pentoxifylline Inhibition of Vasculogenesis in the Neonatal Rat Retina
Hasebe et al.
IOVS 2000;41:2774-2778.
ABSTRACT | FULL TEXT